Table 1.
Patient demographics and baseline characteristics
| Physician choice (n = 35) | ChemoID guided (n = 43) | p value | |
| Age, mean (SD) | 57.5 (10.7) | 57.9 (13.1) | 0.887 |
| Male, no. (%) | 21 (60) | 28 (65) | 0.814 |
| Non-White, no. (%) | 4 (11) | 7 (16) | 0.746 |
| Histopathologic diagnosis,a no. (%) | |||
| Recurrent glioblastoma | 35 (100) | 43 (100) | >0.999 |
| MGMT promoter methylation status, no. (%) | |||
| Methylated | 11 (31.4) | 15 (34.8) | 0.812 |
| Unmethylated | 24 (68.6) | 28 (65.2) | 0.812 |
| IDH1/IDH2 status, no. (%) | |||
| Mutant | 3 (8.5) | 7 (16.2) | 0.498 |
| Wild type | 32 (91.4) | 36 (83.7) | 0.498 |
| Measurable lesions, no. | 50 | 66 | NA |
| Target lesion size, median (range), mm2 | 500 (200–1700) | 500 (200–1900) | >0.999 |
| Site of target lesion(s), no. (%) | |||
| Temporal lobe | 22 (44) | 27 (41) | 0.731 |
| Frontal lobe | 8 (16) | 15 (23) | 0.731 |
| Parietal lobe | 12 (24) | 12 (18) | 0.731 |
| Occipital lobe | 3 (6) | 7 (11) | 0.731 |
| Parietal and occipital | 5 (10) | 5 (8) | 0.731 |
| Cerebellum | 0 | 0 | 0.731 |
| Brain stem | 0 | 0 | 0.731 |
| Insula | 0 | 0 | 0.731 |
| Karnofsky performance status at study entry, no. (%) | |||
| ≤80 | 0 | 0 | >0.999 |
| ≥80 | 35 (100) | 43 (100) | >0.999 |
| Corticosteroid use, no. (%) | |||
| ≤2 mg/day | 2 (5.7) | 4 (9.3) | 0.879 |
| >2 to <4 mg/day | 9 (25.7) | 9 (21) | 0.879 |
| ≥4 mg/day | 6 (17.1) | 6 (13.9) | 0.879 |
| No | 18 (51.5) | 24 (55.8) | 0.879 |
a
Glioblastomas were diagnosed following the 2016 WHO classification.12